The Claim
Combination therapy with photodynamic therapy and ranibizumab achieves complete polyp regression in up to 77.8% of treatment-naïve patients with polypoidal choroidal vasculopathy, which is significantly higher than the rates observed with ranibizumab monotherapy (26.7–34.7%) and photodynamic therapy monotherapy (71.4%), demonstrating superior anatomical resolution of polypoidal lesions.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with ranibizumab results in complete regression of polyps in up to 77.8% of cases, which is higher than the rates seen with either treatment alone.
See the scientific wording
Combination therapy with photodynamic therapy and ranibizumab achieves complete polyp regression in up to 77.8% of treatment-naïve patients with polypoidal choroidal vasculopathy, significantly higher than ranibizumab monotherapy (26.7–34.7%) and PDT monotherapy (71.4%), indicating superior anatomical resolution of polypoidal lesions.
A light-activated treatment destroys abnormal blood vessels in the eye, while a separate injection blocks a protein that causes leaking and swelling. Together, they shut down the abnormal vessels completely and prevent them from coming back.
What the research says
1 studyWhen doctors combine two treatments — a light-based therapy and an eye injection — they can close off the weird blood vessels in the eye better than using either treatment alone. This study shows it works much better together.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.